Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below 200-Day Moving Average – Here’s What Happened

Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.20 and traded as low as $0.1670. Northwest Biotherapeutics shares last traded at $0.1694, with a volume of 2,608,559 shares trading hands.

Northwest Biotherapeutics Trading Down 2.4%

The firm has a market capitalization of $285.91 million, a P/E ratio of -0.01 and a beta of -0.61. The business’s 50 day simple moving average is $0.17 and its two-hundred day simple moving average is $0.20.

Northwest Biotherapeutics (OTCMKTS:NWBO) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The firm had revenue of $0.81 million for the quarter.

Institutional Trading of Northwest Biotherapeutics

An institutional investor recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC bought a new position in Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned approximately 0.07% of Northwest Biotherapeutics at the end of the most recent quarter. 0.04% of the stock is currently owned by institutional investors and hedge funds.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.